Gastric dumping syndrome classification: Difference between revisions

Jump to navigation Jump to search
 
(15 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Gastric dumping syndrome}}
{{Gastric dumping syndrome}}
{{CMG}}
{{CMG}}; {{AE}} {{UA}}


==Overview==
==Overview==
Dumping syndrome can be divided into two classifications. These classifications are based on the onset of symptoms after the first meal.
[[Gastric dumping syndrome|Dumping syndrome]] can be divided into early dumping and late dumping syndrome based upon the timeline of onset of [[symptoms]] and clinical features.


==Classification==
==Classification==
====Early dumping====
Dumping syndrome may be classified based upon the timeline of the onset of [[symptoms]] and clinical features. The following table depicts the major classification systems of dumping syndrome :<ref name="pmid1549803">{{cite journal |vauthors=Eagon JC, Miedema BW, Kelly KA |title=Postgastrectomy syndromes |journal=Surg. Clin. North Am. |volume=72 |issue=2 |pages=445–65 |year=1992 |pmid=1549803 |doi= |url=}}</ref><ref name="pmid1990879">{{cite journal |vauthors=Miedema BW, Kelly KA |title=The Roux operation for postgastrectomy syndromes |journal=Am. J. Surg. |volume=161 |issue=2 |pages=256–61 |year=1991 |pmid=1990879 |doi= |url=}}</ref><ref name="pmid9279532">{{cite journal |vauthors=Vecht J, Gielkens HA, Frölich M, Lamers CB, Masclee AA |title=Vasoactive substances in early dumping syndrome: effects of dumping provocation with and without octreotide |journal=Eur. J. Clin. Invest. |volume=27 |issue=8 |pages=680–4 |year=1997 |pmid=9279532 |doi= |url=}}</ref>
 
{| class="wikitable" style="margin: 1em auto 1em auto"
Early dumping syndrome occurs 15-30 minutes after a meal.<ref name="pmid1549803">{{cite journal |vauthors=Eagon JC, Miedema BW, Kelly KA |title=Postgastrectomy syndromes |journal=Surg. Clin. North Am. |volume=72 |issue=2 |pages=445–65 |year=1992 |pmid=1549803 |doi= |url=}}</ref>  
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Features
* It starts with the intake of a hyperosmolar content.<ref name="pmid27487971">{{cite journal |vauthors=Laurenius A, Engström M |title=Early dumping syndrome is not a complication but a desirable feature of Roux-en-Y gastric bypass surgery |journal=Clin Obes |volume=6 |issue=5 |pages=332–40 |year=2016 |pmid=27487971 |doi=10.1111/cob.12158 |url=}}</ref> This leads to a fluid shift from the blood circulation to the gut which in-turn dehydrates and concentrates the intracellular space.
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Early Dumping
* A decrease in gastric volume <ref name="pmid19724252">{{cite journal |vauthors=Tack J, Arts J, Caenepeel P, De Wulf D, Bisschops R |title=Pathophysiology, diagnosis and management of postoperative dumping syndrome |journal=Nat Rev Gastroenterol Hepatol |volume=6 |issue=10 |pages=583–90 |year=2009 |pmid=19724252 |doi=10.1038/nrgastro.2009.148 |url=}}</ref> via surgery
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Late Dumping
* Pyloric Dysfunction<ref name="pmid19724252">{{cite journal |vauthors=Tack J, Arts J, Caenepeel P, De Wulf D, Bisschops R |title=Pathophysiology, diagnosis and management of postoperative dumping syndrome |journal=Nat Rev Gastroenterol Hepatol |volume=6 |issue=10 |pages=583–90 |year=2009 |pmid=19724252 |doi=10.1038/nrgastro.2009.148 |url=}}</ref>
|-
* Hormones released;<ref name="pmid6780101">{{cite journal |vauthors=Sagor GR, Bryant MG, Ghatei MA, Kirk RM, Bloom SR |title=Release of vasoactive intestinal peptide in the dumping syndrome |journal=Br Med J (Clin Res Ed) |volume=282 |issue=6263 |pages=507–10 |year=1981 |pmid=6780101 |pmc=1504318 |doi= |url=}}</ref><ref name="pmid3726454">{{cite journal |vauthors=Pedersen JH, Beck H, Shokouh-Amiri M, Fischer A |title=Effect of neurotensin in the dumping syndrome |journal=Scand. J. Gastroenterol. |volume=21 |issue=4 |pages=478–82 |year=1986 |pmid=3726454 |doi= |url=}}</ref><ref name="pmid6372067">{{cite journal |vauthors=Lawaetz O, Blackburn AM, Bloom SR, Aritas Y, Ralphs DN |title=Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis |journal=Scand. J. Gastroenterol. |volume=18 |issue=1 |pages=73–80 |year=1983 |pmid=6372067 |doi= |url=}}</ref><ref name="pmid11575444">{{cite journal |vauthors=Gebhard B, Holst JJ, Biegelmayer C, Miholic J |title=Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome |journal=Dig. Dis. Sci. |volume=46 |issue=9 |pages=1915–23 |year=2001 |pmid=11575444 |doi= |url=}}</ref>
|'''Onset'''
** Vasoactive agents (VIP, Neurotensin)
|15-30 minutes after a meal
** Incretins (GIP, GLP-1)
|60-180 minutes after a meal
** Glucose-modulating hormones (Glucagon, Insulin)
|-
* Esophageal surgery may also impair gastric retentive capacity because the accompanying vagotomy causes rapid liquid emptying. Hyperosmolar nutrients in the small bowel presumably cause a shift of fluid from the intravascular compartment (i.e. plasma) to the intestinal lumen, resulting in a reduction in plasma volume, tachycardia, and, rarely, syncope. Movement of fluid into the small bowel may also cause distention and contribute to cramp-like contractions, bloating and diarrhoea. Whether this fluid shift contributes to the pathophysiology of dumping syndrome or is mainly a consequence of this process remains unknown. In favour of the latter interpretation, intravenous fluid substitution is not effective in preventing early dumping symptoms<ref name="pmid14452070">{{cite journal |vauthors=JOHNSON LP, SLOOP RD, JESSEPH JE |title=Etiologic significance of the early symptomatic phase in the dumping syndrome |journal=Ann. Surg. |volume=156 |issue= |pages=173–9 |year=1962 |pmid=14452070 |pmc=1466323 |doi= |url=}}</ref>
|'''Risk Factor'''
* . Another important mechanism involved in the pathophysiology of early dumping syndrome (and also late dumping syndrome as described below) involves the increased release of multiple GI hormones including vasoactive agents (e.g. neurotensin and vasoactive intestinal peptide [VIP]), incretins (e.g. gastric inhibitory polypeptide [GIP] and GLP-1), and glucose modulators (e.g. insulin and glucagon)<ref name="pmid17643905">{{cite journal |vauthors=Tack J |title=Gastric motor disorders |journal=Best Pract Res Clin Gastroenterol |volume=21 |issue=4 |pages=633–44 |year=2007 |pmid=17643905 |doi=10.1016/j.bpg.2007.04.001 |url=}}</ref>.
|[[Bariatrics|Bariatric]] [[Surgery]]
* Enhanced release of these GI hormones may induce discoordinated GI motility and inhibit secretion, as well as elicit hemodynamic effects; for example, neurotensin and vasoactive intestinal polypeptide induce splanchnic vasodilation that results in hypotension and systemic hemoconcentration<ref name="pmid3985800">{{cite journal |vauthors=Sirinek KR, O'Dorisio TM, Howe B, McFee AS |title=Neurotensin, vasoactive intestinal peptide, and Roux-en-Y gastrojejunostomy. Their role in the dumping syndrome |journal=Arch Surg |volume=120 |issue=5 |pages=605–9 |year=1985 |pmid=3985800 |doi= |url=}}</ref>
|[[Hyperosmolar]] [[chyme]]
 
|-
===Late dumping===
|'''Mechanism'''
 
|
Late dumping syndrome occurs between 60-180 minutes.
* Increased release of multiple [[Gastrointestinal tract|gastrointestinal]] [[Hormone|hormones]]
* Rapid glucose absorption
* Decrease in [[Stomach|gastric]] [[volume]]
* Incretin release (GLP-1)
* Impaired [[retention]]
* Amplified insulin secretion
* Possible [[Pylorus|pyloric]] dysfunction
In contrast to the multiple pathophysiologic factors involved in early dumping syndrome, the pathophysiology of late dumping is largely attributable to the development of hyperinsulinemic or reactive hypoglycemia<ref name="pmid9200302">{{cite journal |vauthors=Vecht J, Masclee AA, Lamers CB |title=The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment |journal=Scand. J. Gastroenterol. Suppl. |volume=223 |issue= |pages=21–7 |year=1997 |pmid=9200302 |doi= |url=}}</ref>. Rapid delivery of undigested carbohydrates to the small intestine results in high glucose concentrations that induce a hyperinsulinemic response, resulting in subsequent hypoglycemia and related late dumping symptoms<ref name="pmid1213650">{{cite journal |vauthors=Eloy R, Garaud JC, Moody A, Jaeck D, Grenier JF |title=Jejunal factor stimulating insulin release in the isolated perfused canine pancreas and jejunum |journal=Horm. Metab. Res. |volume=7 |issue=6 |pages=461–7 |year=1975 |pmid=1213650 |doi=10.1055/s-0028-1093704 |url=}}</ref>. Enteral glucose administration is known to induce enhanced insulin release relative to intravenous administration, a process known as the incretin effect. Two GI hormones are believed to play a pivotal role in the incretin effect: glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide and GLP-1. An increased GLP-1 response has been reported in patients after gastric surgery, and a positive correlation has been observed between increasing GLP-1 levels and insulin release<ref name="pmid9794105">{{cite journal |vauthors=Toft-Nielsen M, Madsbad S, Holst JJ |title=Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia |journal=Diabetologia |volume=41 |issue=10 |pages=1180–6 |year=1998 |pmid=9794105 |doi=10.1007/s001250051049 |url=}}</ref>. An additional study suggests that GLP-1 analogues may actually stabilize glucose levels in patients with postprandial hypoglycemia after gastric bypass surgery<ref name="pmid24086087">{{cite journal |vauthors=Abrahamsson N, Engström BE, Sundbom M, Karlsson FA |title=GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication? |journal=Eur. J. Endocrinol. |volume=169 |issue=6 |pages=885–9 |year=2013 |pmid=24086087 |doi=10.1530/EJE-13-0504 |url=}}</ref>. Therefore, an exaggerated endogenous GLP-1 response appears to be the key mediator of the hyperinsulinemic and hypoglycemic effect that is characteristic of late dumping syndrome<ref name="pmid24315990">{{cite journal |vauthors=Salehi M, Gastaldelli A, D'Alessio DA |title=Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass |journal=Gastroenterology |volume=146 |issue=3 |pages=669–680.e2 |year=2014 |pmid=24315990 |pmc=3943944 |doi=10.1053/j.gastro.2013.11.044 |url=}}</ref>. However, the precise mechanism by which GLP-1 contributes to glucose homeostasis and late dumping syndrome is likely to be complex and remains to be fully elucidated.
|
* Rapid [[glucose]] absorption
* [[Incretin]] release ([[Glucagon-like peptide-1|GLP-1]])
* Amplified [[insulin]] [[secretion]]
|-
|'''Symptoms'''
|
* [[Nausea and vomiting|Nausea]]
* [[Bloating]]
* [[Nausea and vomiting|Vomiting]]
* [[Diarrhea]]
* [[Borborygmus]]
* [[Epigastric]] fullness
* [[Abdominal]] [[Cramp|cramps]]
* [[Diaphoresis]]
* Desire to lie down
* [[Headache]]
* [[Flushing]]
* [[Fatigue]]
* [[Dizziness|Lightheadedness]]
* [[Pallor]]
* [[Palpitation|Palpitations]]
* [[Syncope]]
|
* [[Tremor]]
* [[Hunger]]
* [[Perspiration]]
* Difficulty with [[concentration]]
* Decreased [[consciousness]]
|-
|'''Hormones'''
|
* [[Vasoactive]] agents ([[Vasoactive intestinal peptide|VIP]], [[Neurotensin]])
* [[Incretin|Incretins]] ([[Gastric inhibitory polypeptide]]- [[Gastric inhibitory polypeptide|GIP]], [[Glucagon-like peptide-1|glucagon like peptide]]- [[Glucagon-like peptide-1|GLP-1)]]
* [[Glucose]]-modulating [[Hormone|hormones]] ([[Glucagon]], [[Insulin]])
|
* [[Incretin]]
|-
|'''Common Complication'''
|[[Vasomotor]] [[Symptom|symptoms]]
|[[Hypoglycemia]] (high [[Insulin]])
|}


==References==
==References==

Latest revision as of 18:15, 13 December 2017

Gastric dumping syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gastric dumping syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastric dumping syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastric dumping syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastric dumping syndrome classification

CDC on Gastric dumping syndrome classification

Gastric dumping syndrome classification in the news

Blogs on Gastric dumping syndrome classification

Directions to Hospitals Treating Gastric dumping syndrome

Risk calculators and risk factors for Gastric dumping syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Umar Ahmad, M.D.[2]

Overview

Dumping syndrome can be divided into early dumping and late dumping syndrome based upon the timeline of onset of symptoms and clinical features.

Classification

Dumping syndrome may be classified based upon the timeline of the onset of symptoms and clinical features. The following table depicts the major classification systems of dumping syndrome :[1][2][3]

Clinical Features Early Dumping Late Dumping
Onset 15-30 minutes after a meal 60-180 minutes after a meal
Risk Factor Bariatric Surgery Hyperosmolar chyme
Mechanism
Symptoms
Hormones
Common Complication Vasomotor symptoms Hypoglycemia (high Insulin)

References

  1. Eagon JC, Miedema BW, Kelly KA (1992). "Postgastrectomy syndromes". Surg. Clin. North Am. 72 (2): 445–65. PMID 1549803.
  2. Miedema BW, Kelly KA (1991). "The Roux operation for postgastrectomy syndromes". Am. J. Surg. 161 (2): 256–61. PMID 1990879.
  3. Vecht J, Gielkens HA, Frölich M, Lamers CB, Masclee AA (1997). "Vasoactive substances in early dumping syndrome: effects of dumping provocation with and without octreotide". Eur. J. Clin. Invest. 27 (8): 680–4. PMID 9279532.

Template:WH Template:WS